Activation of simulator of interferon genes (STING), which induces the production of proinflammatory factors and immune effector cell activation, is considered a promising strategy for enhanced anti-cancer intervention.
However, several obstacles prevent STING signalling in solid tumours, such as delivered molecules’ rapid degradation, restriction to tumour sites, insufficient intracellular concentrations, and low responsivity.
Well-designed, multifunctional nano-formulations have emerged as optimised platforms for STING activation.
Recently, a variety of nano-formulations have been developed and used in STING activation, thus facilitating immunotherapy in preclinical and clinical stages.
The authors of this article summarise recent advances in nanotechnology-based delivery, activation, and application strategies, which have advanced various aspects of immunotherapy.
Novel STING agonists and their mechanisms in STING-activation-mediated tumour interventions are highlighted, to provide a comprehensive overview and discuss future directions for boosting immunotherapy via STING regulation.
Source: Compuscript Ltd
